Report Library
All Reports
Multiple Myeloma KOL Interview - Western US
January 30, 2025
This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Ongoing Phase III trials are also discussed. Key therapies highlighted include the anti-CD38 antibodies Darzalex and Sarclisa, the CAR-T therapies Abecma and Carvykti, the bispecific antibodies Tecvayli and Elrexfio and the antibody drug-conjugate Blenrep.
Please note that this interview was conducted in November 2024.
If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.
Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: | Multiple Myeloma (MM) |
Additional Resources:
- Podcast: Bispecific Antibodies in Oncology
- Datamonitor Healthcare Oncology Disease Analysis: Multiple Myeloma
- 2022 Multiple Myeloma KOL Interview - US
- 2024 Biomedtracker / Datamonitor Healthcare Post-ASH Report
- 2024 Multiple Myeloma KOL Interview - US Midwest
- 2024 Multiple Myeloma KOL Interview - France